Prospective feasibility and safety assessment of surgical biopsy for patients with newly diagnosed diffuse intrinsic pontine glioma

Nalin Gupta, Liliana C. Goumnerova, Peter Manley, Susan N. Chi, Donna Neuberg, Maneka Puligandla, Jason Fangusaro, Stewart Goldman, Tadanori Tomita, Tord Alden, Arthur Dipatri, Joshua B. Rubin, Karen Gauvain, David Limbrick, Jeffrey Leonard, J. Russel Geyer, Sarah Leary, Samuel Browd, Zhihong Wang, Sandeep Sood & 44 others Anne Bendel, Mahmoud Nagib, Sharon Gardner, Matthias A. Karajannis, David Harter, Kanyalakshmi Ayyanar, William Gump, Daniel C Bowers, Bradley E Weprin, Tobey J. Macdonald, Dolly Aguilera, Barunashish Brahma, Nathan J. Robison, Erin Kiehna, Mark Krieger, Eric Sandler, Philipp Aldana, Ziad Khatib, John Ragheb, Sanjiv Bhatia, Sabine Mueller, Anu Banerjee, Amy Lee Bredlau, Sri Gururangan, Herbert Fuchs, Kenneth J. Cohen, George Jallo, Kathleen Dorris, Michael Handler, Melanie Comito, Mark Dias, Kellie Nazemi, Lissa Baird, Jeff Murray, Neal Lindeman, Jason L. Hornick, Hayley Malkin, Claire Sinai, Lianne Greenspan, Karen D. Wright, Michael Prados, Pratiti Bandopadhayay, Keith L. Ligon, Mark W. Kieran

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Background. Diagnosis of diffuse intrinsic pontine glioma (DIPG) has relied on imaging studies, since the appearance is pathognomonic, and surgical risk was felt to be high and unlikely to affect therapy. The DIPG Biology and Treatment Study (DIPG-BATS) reported here incorporated a surgical biopsy at presentation and stratified subjects to receive FDA-approved agents chosen on the basis of specific biologic targets. Methods. Subjects were eligible for the trial if the clinical features and imaging appearance of a newly diagnosed tumor were consistent with a DIPG. Surgical biopsies were performed after enrollment and prior to definitive treatment. All subjects were treated with conventional external beam radiotherapy with bevacizumab, and then stratified to receive bevacizumab with erlotinib or temozolomide, both agents, or neither agent, based on O6-methylguanine-DNA methyltransferase status and epidermal growth factor receptor expression. Whole-genome sequencing and RNA sequencing were performed but not used for treatment assignment.

Original languageEnglish (US)
Pages (from-to)1547-1555
Number of pages9
JournalNeuro-Oncology
Volume20
Issue number11
DOIs
StatePublished - Oct 9 2018
Externally publishedYes

Fingerprint

Glioma
Biopsy
Safety
temozolomide
RNA Sequence Analysis
Methyltransferases
Therapeutics
Epidermal Growth Factor Receptor
Radiotherapy
Clinical Trials
Genome
DNA
Neoplasms
Bevacizumab

Keywords

  • bevacizumab
  • DIPG
  • erlotinib
  • stereotactic biopsy
  • temozolomide

ASJC Scopus subject areas

  • Oncology
  • Clinical Neurology
  • Cancer Research

Cite this

Gupta, N., Goumnerova, L. C., Manley, P., Chi, S. N., Neuberg, D., Puligandla, M., ... Kieran, M. W. (2018). Prospective feasibility and safety assessment of surgical biopsy for patients with newly diagnosed diffuse intrinsic pontine glioma. Neuro-Oncology, 20(11), 1547-1555. https://doi.org/10.1093/neuonc/noy070

Prospective feasibility and safety assessment of surgical biopsy for patients with newly diagnosed diffuse intrinsic pontine glioma. / Gupta, Nalin; Goumnerova, Liliana C.; Manley, Peter; Chi, Susan N.; Neuberg, Donna; Puligandla, Maneka; Fangusaro, Jason; Goldman, Stewart; Tomita, Tadanori; Alden, Tord; Dipatri, Arthur; Rubin, Joshua B.; Gauvain, Karen; Limbrick, David; Leonard, Jeffrey; Geyer, J. Russel; Leary, Sarah; Browd, Samuel; Wang, Zhihong; Sood, Sandeep; Bendel, Anne; Nagib, Mahmoud; Gardner, Sharon; Karajannis, Matthias A.; Harter, David; Ayyanar, Kanyalakshmi; Gump, William; Bowers, Daniel C; Weprin, Bradley E; Macdonald, Tobey J.; Aguilera, Dolly; Brahma, Barunashish; Robison, Nathan J.; Kiehna, Erin; Krieger, Mark; Sandler, Eric; Aldana, Philipp; Khatib, Ziad; Ragheb, John; Bhatia, Sanjiv; Mueller, Sabine; Banerjee, Anu; Bredlau, Amy Lee; Gururangan, Sri; Fuchs, Herbert; Cohen, Kenneth J.; Jallo, George; Dorris, Kathleen; Handler, Michael; Comito, Melanie; Dias, Mark; Nazemi, Kellie; Baird, Lissa; Murray, Jeff; Lindeman, Neal; Hornick, Jason L.; Malkin, Hayley; Sinai, Claire; Greenspan, Lianne; Wright, Karen D.; Prados, Michael; Bandopadhayay, Pratiti; Ligon, Keith L.; Kieran, Mark W.

In: Neuro-Oncology, Vol. 20, No. 11, 09.10.2018, p. 1547-1555.

Research output: Contribution to journalArticle

Gupta, N, Goumnerova, LC, Manley, P, Chi, SN, Neuberg, D, Puligandla, M, Fangusaro, J, Goldman, S, Tomita, T, Alden, T, Dipatri, A, Rubin, JB, Gauvain, K, Limbrick, D, Leonard, J, Geyer, JR, Leary, S, Browd, S, Wang, Z, Sood, S, Bendel, A, Nagib, M, Gardner, S, Karajannis, MA, Harter, D, Ayyanar, K, Gump, W, Bowers, DC, Weprin, BE, Macdonald, TJ, Aguilera, D, Brahma, B, Robison, NJ, Kiehna, E, Krieger, M, Sandler, E, Aldana, P, Khatib, Z, Ragheb, J, Bhatia, S, Mueller, S, Banerjee, A, Bredlau, AL, Gururangan, S, Fuchs, H, Cohen, KJ, Jallo, G, Dorris, K, Handler, M, Comito, M, Dias, M, Nazemi, K, Baird, L, Murray, J, Lindeman, N, Hornick, JL, Malkin, H, Sinai, C, Greenspan, L, Wright, KD, Prados, M, Bandopadhayay, P, Ligon, KL & Kieran, MW 2018, 'Prospective feasibility and safety assessment of surgical biopsy for patients with newly diagnosed diffuse intrinsic pontine glioma', Neuro-Oncology, vol. 20, no. 11, pp. 1547-1555. https://doi.org/10.1093/neuonc/noy070
Gupta, Nalin ; Goumnerova, Liliana C. ; Manley, Peter ; Chi, Susan N. ; Neuberg, Donna ; Puligandla, Maneka ; Fangusaro, Jason ; Goldman, Stewart ; Tomita, Tadanori ; Alden, Tord ; Dipatri, Arthur ; Rubin, Joshua B. ; Gauvain, Karen ; Limbrick, David ; Leonard, Jeffrey ; Geyer, J. Russel ; Leary, Sarah ; Browd, Samuel ; Wang, Zhihong ; Sood, Sandeep ; Bendel, Anne ; Nagib, Mahmoud ; Gardner, Sharon ; Karajannis, Matthias A. ; Harter, David ; Ayyanar, Kanyalakshmi ; Gump, William ; Bowers, Daniel C ; Weprin, Bradley E ; Macdonald, Tobey J. ; Aguilera, Dolly ; Brahma, Barunashish ; Robison, Nathan J. ; Kiehna, Erin ; Krieger, Mark ; Sandler, Eric ; Aldana, Philipp ; Khatib, Ziad ; Ragheb, John ; Bhatia, Sanjiv ; Mueller, Sabine ; Banerjee, Anu ; Bredlau, Amy Lee ; Gururangan, Sri ; Fuchs, Herbert ; Cohen, Kenneth J. ; Jallo, George ; Dorris, Kathleen ; Handler, Michael ; Comito, Melanie ; Dias, Mark ; Nazemi, Kellie ; Baird, Lissa ; Murray, Jeff ; Lindeman, Neal ; Hornick, Jason L. ; Malkin, Hayley ; Sinai, Claire ; Greenspan, Lianne ; Wright, Karen D. ; Prados, Michael ; Bandopadhayay, Pratiti ; Ligon, Keith L. ; Kieran, Mark W. / Prospective feasibility and safety assessment of surgical biopsy for patients with newly diagnosed diffuse intrinsic pontine glioma. In: Neuro-Oncology. 2018 ; Vol. 20, No. 11. pp. 1547-1555.
@article{fc56cc8f3bc540cda3611cbf411a86a2,
title = "Prospective feasibility and safety assessment of surgical biopsy for patients with newly diagnosed diffuse intrinsic pontine glioma",
abstract = "Background. Diagnosis of diffuse intrinsic pontine glioma (DIPG) has relied on imaging studies, since the appearance is pathognomonic, and surgical risk was felt to be high and unlikely to affect therapy. The DIPG Biology and Treatment Study (DIPG-BATS) reported here incorporated a surgical biopsy at presentation and stratified subjects to receive FDA-approved agents chosen on the basis of specific biologic targets. Methods. Subjects were eligible for the trial if the clinical features and imaging appearance of a newly diagnosed tumor were consistent with a DIPG. Surgical biopsies were performed after enrollment and prior to definitive treatment. All subjects were treated with conventional external beam radiotherapy with bevacizumab, and then stratified to receive bevacizumab with erlotinib or temozolomide, both agents, or neither agent, based on O6-methylguanine-DNA methyltransferase status and epidermal growth factor receptor expression. Whole-genome sequencing and RNA sequencing were performed but not used for treatment assignment.",
keywords = "bevacizumab, DIPG, erlotinib, stereotactic biopsy, temozolomide",
author = "Nalin Gupta and Goumnerova, {Liliana C.} and Peter Manley and Chi, {Susan N.} and Donna Neuberg and Maneka Puligandla and Jason Fangusaro and Stewart Goldman and Tadanori Tomita and Tord Alden and Arthur Dipatri and Rubin, {Joshua B.} and Karen Gauvain and David Limbrick and Jeffrey Leonard and Geyer, {J. Russel} and Sarah Leary and Samuel Browd and Zhihong Wang and Sandeep Sood and Anne Bendel and Mahmoud Nagib and Sharon Gardner and Karajannis, {Matthias A.} and David Harter and Kanyalakshmi Ayyanar and William Gump and Bowers, {Daniel C} and Weprin, {Bradley E} and Macdonald, {Tobey J.} and Dolly Aguilera and Barunashish Brahma and Robison, {Nathan J.} and Erin Kiehna and Mark Krieger and Eric Sandler and Philipp Aldana and Ziad Khatib and John Ragheb and Sanjiv Bhatia and Sabine Mueller and Anu Banerjee and Bredlau, {Amy Lee} and Sri Gururangan and Herbert Fuchs and Cohen, {Kenneth J.} and George Jallo and Kathleen Dorris and Michael Handler and Melanie Comito and Mark Dias and Kellie Nazemi and Lissa Baird and Jeff Murray and Neal Lindeman and Hornick, {Jason L.} and Hayley Malkin and Claire Sinai and Lianne Greenspan and Wright, {Karen D.} and Michael Prados and Pratiti Bandopadhayay and Ligon, {Keith L.} and Kieran, {Mark W.}",
year = "2018",
month = "10",
day = "9",
doi = "10.1093/neuonc/noy070",
language = "English (US)",
volume = "20",
pages = "1547--1555",
journal = "Neuro-Oncology",
issn = "1522-8517",
publisher = "Oxford University Press",
number = "11",

}

TY - JOUR

T1 - Prospective feasibility and safety assessment of surgical biopsy for patients with newly diagnosed diffuse intrinsic pontine glioma

AU - Gupta, Nalin

AU - Goumnerova, Liliana C.

AU - Manley, Peter

AU - Chi, Susan N.

AU - Neuberg, Donna

AU - Puligandla, Maneka

AU - Fangusaro, Jason

AU - Goldman, Stewart

AU - Tomita, Tadanori

AU - Alden, Tord

AU - Dipatri, Arthur

AU - Rubin, Joshua B.

AU - Gauvain, Karen

AU - Limbrick, David

AU - Leonard, Jeffrey

AU - Geyer, J. Russel

AU - Leary, Sarah

AU - Browd, Samuel

AU - Wang, Zhihong

AU - Sood, Sandeep

AU - Bendel, Anne

AU - Nagib, Mahmoud

AU - Gardner, Sharon

AU - Karajannis, Matthias A.

AU - Harter, David

AU - Ayyanar, Kanyalakshmi

AU - Gump, William

AU - Bowers, Daniel C

AU - Weprin, Bradley E

AU - Macdonald, Tobey J.

AU - Aguilera, Dolly

AU - Brahma, Barunashish

AU - Robison, Nathan J.

AU - Kiehna, Erin

AU - Krieger, Mark

AU - Sandler, Eric

AU - Aldana, Philipp

AU - Khatib, Ziad

AU - Ragheb, John

AU - Bhatia, Sanjiv

AU - Mueller, Sabine

AU - Banerjee, Anu

AU - Bredlau, Amy Lee

AU - Gururangan, Sri

AU - Fuchs, Herbert

AU - Cohen, Kenneth J.

AU - Jallo, George

AU - Dorris, Kathleen

AU - Handler, Michael

AU - Comito, Melanie

AU - Dias, Mark

AU - Nazemi, Kellie

AU - Baird, Lissa

AU - Murray, Jeff

AU - Lindeman, Neal

AU - Hornick, Jason L.

AU - Malkin, Hayley

AU - Sinai, Claire

AU - Greenspan, Lianne

AU - Wright, Karen D.

AU - Prados, Michael

AU - Bandopadhayay, Pratiti

AU - Ligon, Keith L.

AU - Kieran, Mark W.

PY - 2018/10/9

Y1 - 2018/10/9

N2 - Background. Diagnosis of diffuse intrinsic pontine glioma (DIPG) has relied on imaging studies, since the appearance is pathognomonic, and surgical risk was felt to be high and unlikely to affect therapy. The DIPG Biology and Treatment Study (DIPG-BATS) reported here incorporated a surgical biopsy at presentation and stratified subjects to receive FDA-approved agents chosen on the basis of specific biologic targets. Methods. Subjects were eligible for the trial if the clinical features and imaging appearance of a newly diagnosed tumor were consistent with a DIPG. Surgical biopsies were performed after enrollment and prior to definitive treatment. All subjects were treated with conventional external beam radiotherapy with bevacizumab, and then stratified to receive bevacizumab with erlotinib or temozolomide, both agents, or neither agent, based on O6-methylguanine-DNA methyltransferase status and epidermal growth factor receptor expression. Whole-genome sequencing and RNA sequencing were performed but not used for treatment assignment.

AB - Background. Diagnosis of diffuse intrinsic pontine glioma (DIPG) has relied on imaging studies, since the appearance is pathognomonic, and surgical risk was felt to be high and unlikely to affect therapy. The DIPG Biology and Treatment Study (DIPG-BATS) reported here incorporated a surgical biopsy at presentation and stratified subjects to receive FDA-approved agents chosen on the basis of specific biologic targets. Methods. Subjects were eligible for the trial if the clinical features and imaging appearance of a newly diagnosed tumor were consistent with a DIPG. Surgical biopsies were performed after enrollment and prior to definitive treatment. All subjects were treated with conventional external beam radiotherapy with bevacizumab, and then stratified to receive bevacizumab with erlotinib or temozolomide, both agents, or neither agent, based on O6-methylguanine-DNA methyltransferase status and epidermal growth factor receptor expression. Whole-genome sequencing and RNA sequencing were performed but not used for treatment assignment.

KW - bevacizumab

KW - DIPG

KW - erlotinib

KW - stereotactic biopsy

KW - temozolomide

UR - http://www.scopus.com/inward/record.url?scp=85054772860&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85054772860&partnerID=8YFLogxK

U2 - 10.1093/neuonc/noy070

DO - 10.1093/neuonc/noy070

M3 - Article

VL - 20

SP - 1547

EP - 1555

JO - Neuro-Oncology

JF - Neuro-Oncology

SN - 1522-8517

IS - 11

ER -